The single-cell and spatial genomics company is planning a 50 percent increase in headcount, including the addition of 100 people to its commercial organization.
Using metagenomic and bacterial reference genome sequences, researchers assembled a collection of bacteriophage genomes from individuals around the world.
Net loss for Q4 and the year included a $406.9 million in-process research and development expense related to the acquisitions of ReadCoor and Cartana.
The administration will expand COVID-19 testing for schools and underserved populations, increase manufacturing of testing supplies, and increase genomic sequencing.
LifeLabs and Multiplex Genomics, a University of Guelph spinout, will work together to provide SARS-CoV-2 testing in Canada and track variants of the virus.
Using whole-genome sequence data for thousands of African American individuals, researchers teased out ancestry effects on polygenic risk of the conditions.
The group is validating a next-generating sequencing assay that detects EGFR mutations in ultrashort circulating tumor DNA in matched plasma and saliva samples.
Genomic, transcriptomic, proteomic, and post-transcriptional modification features in nearly 100 GBM tumors offered clues to tumor biology, revealing four immune subtypes.
The company plans to use the new funding, which will come from the sale of convertible senior notes due 2028, to support unspecified future growth initiatives.
